Krabbe disease treatment market seen reaching $5.03 billion by 2032

By AI, Created 11:01 AM UTC, May 20, 2026, /AGP/ – Maximize Market Research projects the global Krabbe disease treatment market will grow from $2.88 billion in 2024 to $5.03 billion by 2032, fueled by gene therapy development, newborn screening expansion and orphan drug incentives. The report says the shift could broaden early diagnosis and open the door to more presymptomatic treatment for the rare neurological disorder.

Why it matters: - Krabbe disease is a rare neurological disorder with limited treatment options, so any expansion in screening or therapy access can affect outcomes for a small but highly vulnerable patient pool. - The market is projected to grow from $2.88 billion in 2024 to $5.03 billion by 2032, signaling rising investment in rare disease care and a faster path for gene therapy developers. - Expanded newborn screening can identify infants before symptoms appear, which matters because presymptomatic hematopoietic stem cell transplantation remains the most effective current intervention.

What happened: - Maximize Market Research projected the global Krabbe disease treatment market will reach $5.03 billion by 2032 at a 7.22% CAGR. - The report said the market was valued at $2.88 billion in 2024. - The firm tied growth to gene therapy innovation, orphan drug incentives and broader newborn screening programs. - The report highlighted the full sample report for more detail.

The details: - FDA orphan drug and rare pediatric disease designations are helping attract investment into Krabbe disease programs by offering market exclusivity and tax incentives. - Passage Bio’s PBKR03 has received FDA orphan drug and rare pediatric disease designations. - Forge Biologics’ FBX-101 is being studied in the REKLAIM trial across infantile and late-onset Krabbe disease. - The REKLAIM trial uses an AAV-based gene therapy approach targeting GALC deficiency. - The report said FBX-101 is the broadest-enrollment gene therapy trial in Krabbe disease history. - Newborn screening expansion in multiple U.S. states is increasing early detection and widening the pool of infants eligible for presymptomatic HSCT. - HSCT is described in the report as the standard treatment for presymptomatic infants and the only intervention proven to slow disease progression. - Anticonvulsants remain the leading treatment segment for symptom control. - Gene therapy is the fastest-growing treatment segment. - Infantile cases account for 85% to 90% of demand. - North America leads the market because of advanced HSCT infrastructure, newborn screening mandates and a deeper rare disease pipeline. - Europe ranks second, supported by rare disease networks, higher late-onset prevalence and research infrastructure. - The report also said Asia Pacific is emerging as the next frontier for growth.

Between the lines: - The market story is shifting from symptom management toward genetic intervention, and that change could reshape both clinical practice and commercial competition. - The report suggests big pharma interest is increasing, with Pfizer’s $11.6 billion acquisition of Biohaven Pharmaceuticals cited as a signal of deeper commitment to rare CNS disorders. - The strongest near-term upside appears to depend on clinical readouts, regulatory designations and how quickly screening expands enough to find patients before irreversible damage occurs. - The low incidence rate, about 1 in 100,000 live births in the United States, still limits trial sizes and slows evidence generation.

What’s next: - Forge Biologics, Passage Bio and other gene therapy developers will be judged by Phase 1/2 and later-stage clinical results. - FDA Breakthrough Therapy and Fast Track pathways could shorten review timelines for clinical-stage Krabbe candidates. - More U.S. states may continue adopting newborn screening, which would expand the presymptomatic treatment window. - The report expects competitive positioning through 2032 to hinge on clinical milestones and regulatory progress.

The bottom line: - Krabbe disease treatment is moving from supportive care toward a possible genetic-cure era, and the companies that convert early science into approved therapies first are likely to capture the biggest share of a growing rare-disease market.